

Final - June 17, 2019

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

1600 Clifton Road, NE, Tom Harkin Global Communications Center, Kent "Oz" Nelson Auditorium

Atlanta, Georgia 30329

June 26-27, 2019

<u>AGENDA ITEM</u>	<u>PRESIDER/PRESENTER(s)</u>
Wednesday, June 26	
8:00 Welcome & Introductions	Dr. José Romero (ACIP Chair) Dr. Amanda Cohn (ACIP Executive Secretary, CDC)
8:30 Human Papillomavirus Vaccines	
Introduction	Dr. Peter Szilagyi (ACIP, WG Chair)
Background	Dr. Lauri Markowitz (CDC/NCIRD)
9vHPV Immunogenicity and Safety Trial in Mid-Adult Females	Dr. Alain Luxembourg (Merck & Co.)
Overview of Health Economic Models for HPV Vaccination of Mid-Adults	Dr. Harrell Chesson (CDC/NCHHSTP)
Evidence to Recommendations (EtR) Framework	Dr. Elissa Meites (CDC/NCIRD)
Work Group Considerations and Proposed Policy Options	Dr. Lauri Markowitz (CDC/NCIRD)
10:00 Break	
10:15 Pneumococcal Vaccines	
Introduction	Dr. Grace Lee (ACIP, WG Chair)
Considerations for PCV13 use among adults 65 years or older and summary of the Evidence to Recommendations (EtR) Framework	Dr. Almea Matanock (CDC/NCIRD)
Proposed policy options	Dr. Almea Matanock (CDC/NCIRD)
11:45 Lunch	
1:00 Combination Vaccines	
Introduction	Dr. Kelly Moore (ACIP, WG Chair)
Summary and Relevant Evidence to Recommendation Information	Dr. Sara Oliver (CDC/NCIRD)
1:30 Public Comment	
2:10 Break	
2:25 VOTES	
Human Papillomavirus	Dr. Lauri Markowitz (CDC/NCIRD)
Pneumococcal Vaccines	Dr. Almea Matanock (CDC/NCIRD)
VFC VOTES	
Diphtheria, Tetanus, & Pertussis	Mr. Frank Whitlatch (CDC/NCIRD)
<i>Haemophilus influenzae</i> type b	
Hepatitis B	
Polio	
3:25 Break	
3:40 Measles Update	TBD
3:55 Zoster Vaccines	
Introduction	Dr. Kelly Moore (ACIP, WG Chair)
Update: Safety Monitoring and Surveillance for Recombinant Zoster Vaccine (RZV)	Dr. Tom Shimabukuro (CDC/NCEZID)
Herpes Zoster Work Group Summary	Dr. Kathleen Dooling (CDC/NCIRD)
4:30 Pertussis Vaccines	
Introduction	Dr. Henry Bernstein (ACIP, WG Chair)
EtR Framework, Work Group Considerations and Proposed Policy Options	Dr. Fiona Havers (CDC/NCIRD)
5:00 Rabies Vaccine	Dr. Sharon Frey (ACIP, WG Chair)
5:10 Adjourn	

Final - June 17, 2019

Thursday, June 27

8:00 Unfinished Business and Agency Updates

CDC, CMS, DoD, DVA, FDA, HRSA, IHS, NIH, NVPO

8:30 Influenza Vaccines

Introduction

Dr. Chip Walter (ACIP, WG Chair)

2018-19 U.S. Influenza Activity

Ms. Lynette Brammer (CDC/NCIRD)

2018-19 Influenza Vaccine Effectiveness

Dr. Brendan Flannery (CDC/NCIRD)

2018-19 Influenza Vaccine Safety

Dr. Tom Shimabukuro (CDC/NCEZID)

Proposed Recommendations for 2019-20

Dr. Lisa Grohskopf (CDC/NCIRD)

9:45 Break

10:00 Hepatitis A Vaccines

Introduction

Dr. Kelly Moore (ACIP, WG Chair)

Proposed Recommendations for Use of Hepatitis A

Dr. Noele Nelson (CDC/NCHHSTP)

11:15 Break

11:30 Meningococcal Vaccines

Introduction

Dr. David Stephens (ACIP, WG Chair)

Review of Immunogenicity and persistence data,

Dr. Sarah Mbaeyi (CDC/NCIRD)

GRADE, EtR, and policy options for MenB booster doses

Proposed recommendations for use of meningococcal vaccines

Dr. Sarah Mbaeyi (CDC/NCIRD)

12:30 Lunch

1:30 Public Comment

2:10 VOTES & VFC VOTES

Influenza Vaccines

Dr. Lisa Grohskopf (CDC/NCIRD)

Influenza VFC

Mr. Frank Whitlatch (CDC/NCIRD)

Hepatitis A Vaccines

Dr. Noele Nelson (CDC/NCHHSTP)

Hepatitis A

Mr. Frank Whitlatch (CDC/NCIRD)

Meningococcal Vaccines

Dr. Sarah Mbaeyi (CDC/NCIRD)

Meningococcal VFC

Mr. Frank Whitlatch (CDC/NCIRD)

2:55 Break

3:10 Dengue Vaccine

Introduction

Dr. Robert Atmar (ACIP, WG Chair)

Dengue Epidemiology in the U.S.

Dr. Gabriela Paz-Bailey (CDC, NCEZID)

Dengvaxia Phase III Clinical Trials and Long Term Follow Up

Dr. Gustavo Dayan (Sanofi Pasteur)

Work Group Considerations and Next Steps

Dr. Steve Waterman (CDC, NCEZID)

4:10 Adjourn

Acronyms

AI/AN American Indian/Alaska Native

AVA Anthrax vaccine absorbed

CDC Centers for Disease Control & Prevention

CMS Centers for Medicare and Medicaid Services

DoD Department of Defense

DVA Department of Veterans Affairs

EtR Evidence to Recommendations Framework

FDA Food and Drug Administration

GRADE Grading of Recommendations Assessment, Development and Evaluation

Hib *Haemophilus influenzae* type b

HRSA Health Resources and Services Administration

IHS Indian Health Service

MenB Serogroup B meningococcal vaccine

NCHHSTP National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]

NCIRD National Center for Immunization & Respiratory Diseases [of CDC/OID]

NCEZID National Center for Emerging and Zoonotic Diseases [of CDC/OID]

NVPO National Vaccine Program Office

PCV13 13-valent pneumococcal conjugate vaccine

RZV Recombinant zoster vaccine

WG Work Group This document has been archived for historical purposes. (6/17/2019)

VE Vaccine effectiveness